INS and type 1 diabetes mellitus: Typically, 85–90% of T1DM patients develop characteristic anti-insulin antibodies, antibodies against 65 kDa glutamic acid decarboxylase (GAD65), insulinoma-associated protein 2 (1A-2), and zinc transporter 8 (ZNT8).